Mostrar el registro sencillo del ítem

dc.contributor.authorGomez Rial, Jose 
dc.contributor.authorCurrás Tuala, María José
dc.contributor.authorRivero Calle, Irene 
dc.contributor.authorGómez Carballa, Alberto
dc.contributor.authorCebey López, Miriam
dc.contributor.authorRodríguez-Tenreiro Sánchez, Carmen
dc.contributor.authorDACOSTA URBIETA, ANA ISABEL 
dc.contributor.authorRIVERO VELASCO, CARMEN 
dc.contributor.authorRodríguez Núñez, Nuria 
dc.contributor.authorTRASTOY PENA, ROCIO 
dc.contributor.authorRodríguez García, Javier 
dc.contributor.authorSalas Ellacuriaga, Antonio
dc.contributor.authorMartinón Torres, Federico 
dc.date.accessioned2022-04-26T07:42:39Z
dc.date.available2022-04-26T07:42:39Z
dc.date.issued2020
dc.identifier.issn1664-3224
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/33072099es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16513
dc.description.abstractBackground: Emerging evidence indicates a potential role for monocytes in COVID-19 immunopathology. We investigated two soluble markers of monocyte activation, sCD14 and sCD163, in COVID-19 patients, with the aim of characterizing their potential role in monocyte-macrophage disease immunopathology. To the best of our knowledge, this is the first study of its kind. Methods: Fifty-nine SARS-Cov-2 positive hospitalized patients, classified according to ICU or non-ICU admission requirement, were prospectively recruited and analyzed by ELISA for levels of sCD14 and sCD163, along with other laboratory parameters, and compared to a healthy control group. Results: sCD14 and sCD163 levels were significantly higher among COVID-19 patients, independently of ICU admission requirement, compared to the control group. We found a significant correlation between sCD14 levels and other inflammatory markers, particularly Interleukin-6, in the non-ICU patients group. sCD163 showed a moderate positive correlation with the time lapsed from admission to sampling, independently of severity group. Treatment with corticoids showed an interference with sCD14 levels, whereas hydroxychloroquine and tocilizumab did not. Conclusions: Monocyte-macrophage activation markers are increased and correlate with other inflammatory markers in SARS-Cov-2 infection, in association to hospital admission. These data suggest a preponderant role for monocyte-macrophage activation in the development of immunopathology of COVID-19 patients.en
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshMacrophage Activation*
dc.subject.meshAdult*
dc.subject.meshMiddle Aged*
dc.subject.meshMacrophages*
dc.subject.meshAdrenal Cortex Hormones*
dc.subject.meshInterleukin-6*
dc.subject.meshMonocytes*
dc.subject.meshPatient Admission*
dc.subject.meshAntibodies*
dc.subject.meshHumans*
dc.subject.meshTime Factors*
dc.subject.meshHydroxychloroquine*
dc.subject.meshIntensive Care Units*
dc.subject.meshAged*
dc.titleIncreased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathologyen
dc.typeJournal Articlees
dc.authorsophosGómez-Rial, J.;Currás-Tuala, M. J.;Rivero-Calle, I.;Gómez-Carballa, A.;Cebey-López, M.;Rodríguez-Tenreiro, C.;Dacosta-Urbieta, A.;Rivero-Velasco, C.;Rodríguez-Núñez, N.;Trastoy-Pena, R.;Rodríguez-García, J.;Salas, A.;Martinón-Torres, F.
dc.identifier.doi10.3389/fimmu.2020.560381
dc.identifier.pmid33072099
dc.identifier.sophos39101
dc.journal.titleFrontiers in Immunologyes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Análise clínicoses
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Medicina intensivaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Microbioloxíaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Neumoloxíaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Pediatríaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)es
dc.page.initial560381es
dc.rights.accessRightsopenAccess
dc.subject.decsinterleucina-6*
dc.subject.decsadmisión de pacientes*
dc.subject.decsmediana edad*
dc.subject.decshormonas de la corteza suprarrenal*
dc.subject.decsanticuerpos*
dc.subject.decsadulto*
dc.subject.decsanciano*
dc.subject.decsmonocitos*
dc.subject.decshumanos*
dc.subject.decsfactores de tiempo*
dc.subject.decsunidades de cuidados intensivos*
dc.subject.decshidroxicloroquina*
dc.subject.decsmacrófagos*
dc.subject.decsactivación de macrófagos*
dc.subject.keywordCHUSes
dc.subject.keywordIDISes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number11es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional